Equities

IGEA Pharma NV

IGEA Pharma NV

Actions
  • Price (CHF)0.118
  • Today's Change0.001 / 0.85%
  • Shares traded100.00
  • 1 Year change-68.95%
  • Beta-1.7677
Data delayed at least 15 minutes, as of Jun 29 2022 08:09 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

IGEA Pharma NV is a biopharmaceutical company based in the Netherlands. The Company focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The Company develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer’s disease. The Company offers its services in the Netherlands.

  • Revenue in CHF (TTM)31.01k
  • Net income in CHF-839.28k
  • Incorporated2017
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Addex Therapeutics Ltd2.47m-18.38m12.40m28.00--0.5557--5.01-0.5203-0.52030.07060.34190.1111--27.7588,386.79-82.51-43.18-102.20-50.38-----742.76-279.82---64.690.0309---18.7151.13-18.19--22.97--
Newron Pharmaceuticals SpA5.80m-15.00m26.28m25.00--8.40--4.53-0.8406-0.84060.3250.17530.1133--3.64232,019.40-29.31-25.64-32.70-28.1797.9786.47-258.61-216.08---4.640.9327--9.594.0029.04---22.60--
IGEA Pharma NV31.01k-839.28k39.49m--------1,273.34-0.0337-0.03370.0013-0.00540.043919.220.2701---119.94-82.99-522.70-117.39-703.70-1,067.77-2,729.63-5,422.790.2301--2.88--5,557.14--40.72------
Spexis AG0.00-11.86m52.35m----1.72-----0.8155-0.81550.000.63330.00-------24.54---34.72-------------0.55790.1832---100.00--73.61------
Santhera Pharmaceuticals Holding AG-1.60m-55.53m73.73m39.00--37.34-----1.68-1.68-0.04670.0268-0.01778.29---40,897.44-61.76-48.15-94.15-60.86--80.16---172.870.7386-7.270.97---110.63--17.93---47.47--
Wockhardt Bio AG316.91m-42.95m82.19m----0.2754--0.2594-0.7698-0.76986.105.750.47921.802.50---6.50-1.96-8.19-3.0051.4451.88-13.55-4.233.90-3.450.5092---15.93-8.7151.896.81-17.47--
RELIEF THERAPEUTICS Holding SA3.32m-34.71m137.25m55.00--0.7047--41.33-0.0096-0.00960.00090.04410.0202----60,381.82-21.05-17.42-22.89-18.9277.42---1,045.02-1,372.002.77-389.090.023----194.47-343.34--316.02--
Xlife Sciences AG550.78k14.03m160.08m12.0018.080.985611.65290.641.681.680.096330.840.0032--0.507645,898.337.82--7.88--5.00--2,481.90------0.1989---22.92--1,943.56------
Data as of Jun 29 2022. Currency figures normalised to IGEA Pharma NV's reporting currency: Swiss Franc CHF

Institutional shareholders

0.13%Per cent of shares held by top holders
HolderShares% Held
WBS H�nicke Verm�gensverwaltung GmbHas of 31 Dec 2021400.00k0.12%
Lemanik SAas of 30 Jun 202131.87k0.01%
Data from 31 Dec 2021 - 31 May 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.